293 related articles for article (PubMed ID: 21729418)
1. Amyloid imaging.
Villemagne VL; Rowe CC
Int Psychogeriatr; 2011 Sep; 23 Suppl 2():S41-9. PubMed ID: 21729418
[TBL] [Abstract][Full Text] [Related]
2. Amyloid imaging in Alzheimer's disease and other dementias.
Fodero-Tavoletti MT; Cappai R; McLean CA; Pike KE; Adlard PA; Cowie T; Connor AR; Masters CL; Rowe CC; Villemagne VL
Brain Imaging Behav; 2009 Sep; 3(3):246-61. PubMed ID: 22005989
[TBL] [Abstract][Full Text] [Related]
3. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
Villemagne VL; Rowe CC
J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
[TBL] [Abstract][Full Text] [Related]
4. The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.
Villemagne VL; Fodero-Tavoletti MT; Pike KE; Cappai R; Masters CL; Rowe CC
Mol Neurobiol; 2008 Aug; 38(1):1-15. PubMed ID: 18690556
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
6. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
7. Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis.
Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
J Alzheimers Dis; 2016 Sep; 54(2):559-68. PubMed ID: 27567846
[TBL] [Abstract][Full Text] [Related]
8. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
Hatashita S; Yamasaki H
PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
[TBL] [Abstract][Full Text] [Related]
9. Effect of APOE ε4 genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment.
Li W; Li R; Yan S; Zhao Z; Shan Y; Qi Z; Lu J;
Eur J Neurol; 2023 Mar; 30(3):587-596. PubMed ID: 36448771
[TBL] [Abstract][Full Text] [Related]
10. Neuroimaging biomarkers in Alzheimer's disease and other dementias.
Villemagne VL; Chételat G
Ageing Res Rev; 2016 Sep; 30():4-16. PubMed ID: 26827785
[TBL] [Abstract][Full Text] [Related]
11. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging of dementia.
Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
[TBL] [Abstract][Full Text] [Related]
13. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
14. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
15. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
[TBL] [Abstract][Full Text] [Related]
16. Perfusion SPECT and FDG-PET.
Herholz K
Int Psychogeriatr; 2011 Sep; 23 Suppl 2():S25-31. PubMed ID: 21729421
[TBL] [Abstract][Full Text] [Related]
17. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.
d'Oleire Uquillas F; Jacobs HIL; Hanseeuw B; Marshall GA; Properzi M; Schultz AP; LaPoint MR; Johnson KA; Sperling RA; Vannini P
Neuroimage Clin; 2018; 17():388-396. PubMed ID: 29159051
[TBL] [Abstract][Full Text] [Related]
18. Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease.
Kljajevic V; Grothe MJ; Ewers M; Teipel S;
Neurobiol Aging; 2014 Sep; 35(9):1973-81. PubMed ID: 24811241
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and acceptance of simultaneous amyloid PET/MRI.
Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
[TBL] [Abstract][Full Text] [Related]
20. Imaging beta-amyloid burden in aging and dementia.
Rowe CC; Ng S; Ackermann U; Gong SJ; Pike K; Savage G; Cowie TF; Dickinson KL; Maruff P; Darby D; Smith C; Woodward M; Merory J; Tochon-Danguy H; O'Keefe G; Klunk WE; Mathis CA; Price JC; Masters CL; Villemagne VL
Neurology; 2007 May; 68(20):1718-25. PubMed ID: 17502554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
